Immunovant Historical Financial Ratios

IMVT Stock

USD 18.42 0.03 0.16%

Immunovant is lately reporting on over 94 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 3.48 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Immunovant financial condition quickly.

Quick Ratio Current Ratio

Build AI portfolio with Immunovant Stock

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

About Immunovant Financial Ratios Analysis

ImmunovantFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immunovant investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immunovant financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immunovant history.

Immunovant Financial Ratios Chart

At this time, Immunovant's Book Value Per Share is comparatively stable compared to the past year. Capex To Depreciation is likely to gain to 2.60 in 2025, whereas Operating Cash Flow Per Share is likely to drop (2.60) in 2025.

Average Payables Payables Turnover Cash Per Share Days Payables Outstanding

Add Fundamental

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Immunovant's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immunovant current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.At this time, Immunovant's Book Value Per Share is comparatively stable compared to the past year. Capex To Depreciation is likely to gain to 2.60 in 2025, whereas Operating Cash Flow Per Share is likely to drop (2.60) in 2025.

	2022	2023	2024	2025 (projected)
Current Ratio	9.34	13.7	11.16	7.55
Net Debt To EBITDA	1.79	2.35	2.12	1.66

Current Ratio Net Debt To E B I T D A

Immunovant fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield
Ptb Ratio		-0.18	0.25	0.27	0.08	0.2	1.0	0.27	-0.28	0.35	0.15	-0.09	0.14	-0.19	0.01	-0.02	-0.01	0.01	0.16	0.32	-0.28	-0.05	-1.0	0.28	-0.05	0.33
Book Value Per Share	-0.18		0.86	0.85	-0.53	-0.87	-0.18	0.85	-0.85	0.81	-0.75	0.31	-0.65	0.97	-0.77	0.09	-0.2	-0.77	-0.82	-0.64	-0.85	-0.66	0.2	0.85	-0.66	0.82
Free Cash Flow Yield	0.25	0.86		1.0	-0.34	-0.86	0.25	1.0	-1.0	0.99	-0.64	0.39	-0.59	0.85	-0.83	0.09	0.07	-0.83	-0.72	-0.55	-1.0	-0.77	-0.22	1.0	-0.77	1.0
Operating Cash Flow Per Share	0.27	0.85	1.0		-0.3	-0.85	0.27	1.0	-1.0	1.0	-0.64	0.39	-0.6	0.84	-0.82	0.03	0.06	-0.82	-0.72	-0.58	-1.0	-0.74	-0.24	1.0	-0.74	0.99
Average Payables	0.08	-0.53	-0.34	-0.3		0.3	0.08	-0.3	0.36	-0.29	0.27	0.12	0.13	-0.31	0.08	-0.46	0.23	0.08	0.26	-0.15	0.36	0.05	-0.09	-0.36	0.05	-0.33
Capex To Depreciation	0.2	-0.87	-0.86	-0.85	0.3		0.2	-0.85	0.85	-0.81	0.8	-0.47	0.76	-0.88	0.78	-0.23	-0.28	0.78	0.73	0.65	0.85	0.71	-0.22	-0.85	0.71	-0.82
Pb Ratio	1.0	-0.18	0.25	0.27	0.08	0.2		0.27	-0.28	0.35	0.15	-0.09	0.14	-0.19	0.01	-0.02	-0.01	0.01	0.16	0.32	-0.28	-0.05	-1.0	0.28	-0.05	0.33
Free Cash Flow Per Share	0.27	0.85	1.0	1.0	-0.3	-0.85	0.27		-1.0	1.0	-0.64	0.39	-0.6	0.84	-0.82	0.03	0.06	-0.82	-0.72	-0.58	-1.0	-0.74	-0.24	1.0	-0.74	0.99
Roic	-0.28	-0.85	-1.0	-1.0	0.36	0.85	-0.28	-1.0		-0.99	0.64	-0.37	0.59	-0.84	0.8	-0.09	-0.06	0.8	0.71	0.53	1.0	0.73	0.26	-1.0	0.73	-1.0
Net Income Per Share	0.35	0.81	0.99	1.0	-0.29	-0.81	0.35	1.0	-0.99		-0.61	0.37	-0.57	0.8	-0.79	0.04	0.06	-0.79	-0.69	-0.53	-0.99	-0.73	-0.33	1.0	-0.73	1.0
Days Of Inventory On Hand	0.15	-0.75	-0.64	-0.64	0.27	0.8	0.15	-0.64	0.64	-0.61		-0.42	0.97	-0.75	0.52	-0.28	0.02	0.52	0.72	0.51	0.64	0.43	-0.17	-0.64	0.43	-0.61
Payables Turnover	-0.09	0.31	0.39	0.39	0.12	-0.47	-0.09	0.39	-0.37	0.37	-0.42		-0.53	0.35	-0.37	0.09	0.24	-0.37	-0.72	-0.2	-0.37	-0.34	0.1	0.37	-0.34	0.37
Average Inventory	0.14	-0.65	-0.59	-0.6	0.13	0.76	0.14	-0.6	0.59	-0.57	0.97	-0.53		-0.68	0.44	-0.15	-0.02	0.44	0.74	0.55	0.59	0.34	-0.15	-0.59	0.34	-0.55
Cash Per Share	-0.19	0.97	0.85	0.84	-0.31	-0.88	-0.19	0.84	-0.84	0.8	-0.75	0.35	-0.68		-0.81	0.0	-0.16	-0.81	-0.82	-0.74	-0.84	-0.7	0.22	0.84	-0.7	0.81
Pocfratio	0.01	-0.77	-0.83	-0.82	0.08	0.78	0.01	-0.82	0.8	-0.79	0.52	-0.37	0.44	-0.81		-0.07	-0.13	1.0	0.65	0.59	0.8	0.98	-0.03	-0.8	0.98	-0.82
Interest Coverage	-0.02	0.09	0.09	0.03	-0.46	-0.23	-0.02	0.03	-0.09	0.04	-0.28	0.09	-0.15	0.0	-0.07		0.45	-0.07	0.09	0.53	-0.09	-0.2	0.02	0.09	-0.2	0.1
Capex To Operating Cash Flow	-0.01	-0.2	0.07	0.06	0.23	-0.28	-0.01	0.06	-0.06	0.06	0.02	0.24	-0.02	-0.16	-0.13	0.45		-0.13	0.24	0.12	-0.06	-0.25	0.01	0.06	-0.25	0.08
Pfcf Ratio	0.01	-0.77	-0.83	-0.82	0.08	0.78	0.01	-0.82	0.8	-0.79	0.52	-0.37	0.44	-0.81	1.0	-0.07	-0.13		0.65	0.59	0.8	0.98	-0.03	-0.8	0.98	-0.82
Days Payables Outstanding	0.16	-0.82	-0.72	-0.72	0.26	0.73	0.16	-0.72	0.71	-0.69	0.72	-0.72	0.74	-0.82	0.65	0.09	0.24	0.65		0.61	0.71	0.52	-0.18	-0.71	0.52	-0.69
Income Quality	0.32	-0.64	-0.55	-0.58	-0.15	0.65	0.32	-0.58	0.53	-0.53	0.51	-0.2	0.55	-0.74	0.59	0.53	0.12	0.59	0.61		0.53	0.44	-0.33	-0.53	0.44	-0.5
Roe	-0.28	-0.85	-1.0	-1.0	0.36	0.85	-0.28	-1.0	1.0	-0.99	0.64	-0.37	0.59	-0.84	0.8	-0.09	-0.06	0.8	0.71	0.53		0.73	0.26	-1.0	0.73	-1.0
Ev To Operating Cash Flow	-0.05	-0.66	-0.77	-0.74	0.05	0.71	-0.05	-0.74	0.73	-0.73	0.43	-0.34	0.34	-0.7	0.98	-0.2	-0.25	0.98	0.52	0.44	0.73		0.03	-0.73	1.0	-0.76
Pe Ratio	-1.0	0.2	-0.22	-0.24	-0.09	-0.22	-1.0	-0.24	0.26	-0.33	-0.17	0.1	-0.15	0.22	-0.03	0.02	0.01	-0.03	-0.18	-0.33	0.26	0.03		-0.26	0.03	-0.31
Return On Tangible Assets	0.28	0.85	1.0	1.0	-0.36	-0.85	0.28	1.0	-1.0	1.0	-0.64	0.37	-0.59	0.84	-0.8	0.09	0.06	-0.8	-0.71	-0.53	-1.0	-0.73	-0.26		-0.73	1.0
Ev To Free Cash Flow	-0.05	-0.66	-0.77	-0.74	0.05	0.71	-0.05	-0.74	0.73	-0.73	0.43	-0.34	0.34	-0.7	0.98	-0.2	-0.25	0.98	0.52	0.44	0.73	1.0	0.03	-0.73		-0.76
Earnings Yield	0.33	0.82	1.0	0.99	-0.33	-0.82	0.33	0.99	-1.0	1.0	-0.61	0.37	-0.55	0.81	-0.82	0.1	0.08	-0.82	-0.69	-0.5	-1.0	-0.76	-0.31	1.0	-0.76

Click cells to compare fundamentals

Immunovant Account Relationship Matchups

Immunovant fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	3.6	1.29	5.27	7.07	3.66	3.48
Book Value Per Share	4.46	4.28	2.95	4.47	4.67	4.9
Free Cash Flow Yield	(0.0794)	(0.0593)	(0.18)	(0.0987)	(0.0492)	(0.15)
Operating Cash Flow Per Share	(0.95)	(0.97)	(1.53)	(1.55)	(2.48)	(2.6)
Capex To Depreciation	3.23	2.02	1.02	1.56	2.01	2.6
Pb Ratio	3.6	1.29	5.27	7.07	3.66	3.48
Free Cash Flow Per Share	(0.95)	(0.97)	(1.53)	(1.55)	(2.48)	(2.61)
Roic	(0.27)	(0.33)	(0.55)	(0.46)	(0.62)	(0.59)
Net Income Per Share	(1.22)	(1.43)	(1.71)	(1.88)	(2.73)	(2.87)
Payables Turnover	0.41	0.0661	0.98	0.0323	0.0291	0.0276
Cash Per Share	4.56	4.5	3.06	4.6	4.71	2.72
Pocfratio	(16.89)	(5.7)	(10.14)	(20.38)	(6.89)	(7.24)
Capex To Operating Cash Flow	(0.00252)	(0.002394)	(0.001047)	(0.00168)	(0.002019)	(0.00212)
Pfcf Ratio	(16.85)	(5.68)	(10.13)	(20.34)	(6.88)	(7.22)
Days Payables Outstanding	889.46	5.5K	372.99	11.3K	13.0K	8.5K
Income Quality	0.8	0.78	0.68	0.89	0.83	0.91
Roe	(0.71)	(0.27)	(0.33)	(0.58)	(0.42)	(0.56)
Ev To Operating Cash Flow	(12.13)	(1.06)	(8.15)	(17.41)	(4.99)	(5.24)
Pe Ratio	(13.1)	(3.86)	(9.05)	(16.83)	(6.26)	(6.57)
Return On Tangible Assets	(0.26)	(0.3)	(0.52)	(0.39)	(0.53)	(0.56)
Ev To Free Cash Flow	(12.1)	(1.06)	(8.14)	(17.38)	(4.98)	(5.23)
Earnings Yield	(0.0763)	(0.26)	(0.11)	(0.0594)	(0.16)	(0.17)
Net Debt To E B I T D A	3.72	3.16	1.79	2.35	2.12	1.66
Current Ratio	21.79	11.52	9.34	13.7	11.16	7.55
Tangible Book Value Per Share	4.46	4.28	2.95	4.47	4.67	4.9
Shareholders Equity Per Share	4.46	4.28	2.95	4.47	4.67	4.9
Debt To Equity	0.008728	0.005032	0.003366	2.23E-4	1.39E-4	1.32E-4
Capex Per Share	0.002393	0.002316	0.001601	0.002607	0.005007	0.005258
Graham Net Net	4.33	4.17	2.71	4.28	4.27	2.16
Interest Debt Per Share	0.0389	0.0275	0.11	9.99E-4	6.47E-4	6.14E-4
Debt To Assets	0.008284	0.004585	0.003006	2.07E-4	1.26E-4	1.2E-4
Enterprise Value Over E B I T D A	(9.47)	(0.73)	(7.32)	(13.82)	(15.89)	(16.68)
Price Earnings Ratio	(13.1)	(3.86)	(9.05)	(16.83)	(6.26)	(6.57)
Price Book Value Ratio	3.6	1.29	5.27	7.07	3.66	3.48
Days Of Payables Outstanding	889.46	5.5K	372.99	11.3K	13.0K	8.5K
Price To Operating Cash Flows Ratio	(16.89)	(5.7)	(10.14)	(20.38)	(6.89)	(7.24)
Price To Free Cash Flows Ratio	(16.85)	(5.68)	(10.13)	(20.34)	(6.88)	(7.22)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Immunovant Historical Financial Ratios

About Immunovant Financial Ratios Analysis

Immunovant Financial Ratios Chart

Average Payables

Payables Turnover

Immunovant fundamentals Correlations

Immunovant Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunovant fundamentals Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Immunovant Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Operating Cash Flow Per Share	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Free Cash Flow Yield
Return On Tangible Assets	+ 1.0	Free Cash Flow Yield
Earnings Yield	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share

Earnings Yield	- 1.0	Roe
Return On Tangible Assets	- 1.0	Roe
Earnings Yield	- 1.0	Roic
Return On Tangible Assets	- 1.0	Roic
Roe	- 1.0	Free Cash Flow Per Share
Roic	- 1.0	Free Cash Flow Per Share